text stringlengths 0 197k |
|---|
Caregivers in the Family Navigation condition will receive 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom. |
Researchers will compare participants who receive family navigation to participants who receive the standard of care (educational materials) to see if family navigation outperforms the standard of care. conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: P... |
<|newrecord|> nctId: NCT06291233 id: HUM00236812 id: 1R01MH132656-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01MH132656-01 briefTitle: A Hybrid Effectiveness-Implementation Randomized Clinical Trial (RCT) of Virtual Interview Training for Autistic Transition-Age Youth overallStatus: ENROLLING_BY_INVITATI... |
Participants will be randomized to use Virtual Interview Training (VIT) or continue services as usual (active control group). conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 200 type: ESTIMATED name: ... |
<|newrecord|> nctId: NCT06291220 id: M24-291 id: 2023-507637-19 type: OTHER domain: EU CT briefTitle: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) overallStatus: NO... |
ABBV-453 is an investigational drug for the treatment of CLL and SLL. There are 2 parts to this study. In part A participants will be placed 1 of 5 cohorts with a specific target dose for each cohort and receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the appropriate target... |
Participants in part A will placed into 1 of 5 cohorts with a specific target dose for each cohort and will receive intravenous (IV) obinutuzumab as part of the debulking period, followed by escalating doses of oral ABBV-453 until the appropriate target dose is achieved. Participants in part B will be place in one of 2... |
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects. conditions: Chronic Ly... |
<|newrecord|> nctId: NCT06291207 id: AD-224P3 briefTitle: A Study to Evaluate the Efficacy and Safety of AD-224 overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-03-04 date: 2024-03-06 name: Addpharma Inc. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the ef... |
<|newrecord|> nctId: NCT06291194 id: 22DE30902 briefTitle: Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients overallStatus: RECRUITING date: 2023-11-10 date: 2024-05 date: 2024-05 date: 2024-03-04 date: 2024-04-08 name: AJU Pharm Co., Ltd. class: INDUSTRY name: GL Pharm Tech Corporation briefSummary: This ... |
<|newrecord|> nctId: NCT06291181 id: Soh-Med-24-01-05MD briefTitle: Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals overallStatus: COMPLETED dat... |
The pathogenic mechanisms enabling S. aureus to cause serious infections could include: biofilm which protects organisms from host immune response; opsonophagocytosis and antimicrobial agents, thus leading to chronic and persistent infections. |
Antibiotic resistance associated with S.aureus infections is a great concern for the clinicians to prevent spread of infections. Methicillin was commonly used for these infections before the emergence of MRSA which is developed due to irrational use of antibiotics, prolonged hospital stay, nasal and hand carriage in he... |
Mupirocin act by inhibiting the protein synthesis of bacteria by binding specifically to isoleucyl-tRNAsynthetase enzyme. The irrational use of Mupirocin among patients and its carriage in health care staff has led to the emergence of resistance to this antibiotic. . |
MupA, plasmid mediated gene, has a great role in mupirocinresistence as it had a supplementary modified isoleucyltRNAsynthetase which leads to the high level resistance to Mupirocin. The mupA gene has the ability to facilitate and disseminate the resistance mechanism in different patterns . |
Linezolid,thefirstoxazolidinonedrug,waslaunchedin2001andis still displaying excellent in vitro activity against Staphylococcus epidermidis on a global scale,although outbreaks of linezolidresistant S. epidermidis (LRSE) are occasionally reported.. |
Linezolid resistance is mediated by, mutations in the 23S rRNA gene, altering the drug-binding site, and/or the 50S ribosomal proteins L3, L4 and L22, impairing linezolid binding;,Oracquisition of the primarily plasmid-encoded genes cfr, encoding a methyltransferase, or optrA, encoding an ABC transporter, or the cfr ho... |
While cfr can mediate the PhLOPSA phenotype (resistance to phenicols, lincosamides,oxazolidinones, pleuromutilins and streptogramin A compounds), optrA confers oxazolidinone and phenicolresistance only.. |
Pathogenecity of S. aureus is regulated by various factors ,one of them is the accessory gene regulatory (agr) system. It consists of 2 divergently transcribed loci (3 kb) controlled by means of 2 promoters P2 and P3. Most of clinical isolates of acute infections have a functional agr system and all, like strains, prod... |
Agr deficiency has been related to increased biofilm formation because RNAIII reduces the expression of surface adhesins and increases the production of capsule, toxins, and proteases. The agr system is supposed to regulate over 70 genes, 23 of which are renowned virulence factors. |
There are 2 classes of virulence factors regulated by agr. The first class includes virulence factors implicated in attachment to the host and immune evasion, whereas the second class contains genes engaged in the production of exoproteins related to invasion and toxin production . The activation of the agr system swit... |
Major virulence factors in S. aureus, exfoliative toxins (ETs), toxic shock syndrome toxin (TSST-1), and staphylococcal enterotoxins (SEs) are involved in host colonization, invasion of damaged skin and mucus, gastrointestinal infection, and prevarication of host defense mechanisms. Indeed, agr operon including agrA, a... |
Moreover, S. aureus can be stratified into 4 different groups (agr I, agr II, agr III, and agr IV) according to the sequences of agrC (auto inducing peptide) and agrD (cyclic AIP) genes. It is stated that agr types are different in their properties and prevalence in various geographical areas thus, identification of pr... |
<|newrecord|> nctId: NCT06291168 id: CMT002 briefTitle: Comparison of The Effectiveness of Spinal Manipulation and Yoga in Chronic Low Back Pain acronym: CTESMYCLBP overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-03-01 date: 2024-06-01 date: 2024-03-04 date: 2024-03-04 name: SEFA HAKTAN HATIK class: OTHER... |
<|newrecord|> nctId: NCT06291155 id: HUM00222335 briefTitle: Renal Mechanism of SGLT2 Inhibition overallStatus: RECRUITING date: 2024-01-01 date: 2026-12-31 date: 2028-06-30 date: 2024-03-04 date: 2024-03-04 name: University of Michigan class: OTHER name: University of Colorado, Denver name: Renal Pre-Competitive Conso... |
Participants will be asked to sign a consent and complete a screening visit prior to study entry including the following procedures for this study: |
Consent and Screening: |
* Laboratory tests to determine baseline health |
* Ultrasound to measure kidney size and ensure presence of 2 functioning kidneys |
Month 0: |
* Study entry kidney MRI (day 0) |
* Study entry kidney biopsy (within 30 days of MRI) |
* Study entry visit for dispensing 100 mg/daily Canagliflozin medication 3 month supply |
Month 3: |
* Study visit to dispense remaining 3 months of 100 mg/daily Canagliflozin medication |
* Review of systems |
Month 6: |
* Follow-up kidney MRI |
* Follow-up kidney biopsy |
Study participants will also be requested to provide blood and urine samples for biobanking purposes. They will also be provided the opportunity to provide a stool sample at two time points, as well as the option to participate in a related study collecting samples to create induced Pluripotent Stem Cells (iPSCs). |
Participants will be compensated for their time and loss of work time, additionally, a nominal additional compensation for optional stool and iPSC samples. conditions: Type 2 Diabetes conditions: Diabetic Kidney Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP intervention... |
<|newrecord|> nctId: NCT06291142 id: R129030 id: IRAS 315004 type: OTHER domain: IRAS briefTitle: Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot overallStatus: ENROLLING_BY_INVITATION date: 2023-11-22 date: 2024-09 date: 2025-03 date: 2024-03-04 date: 2024-03-08 name: University of Manchester class: ... |
* Can a range of healthcare professionals, including non-specialists, use the capillaroscopy image acquisition system to take high quality images that can be used to create a clinical report? |
* Can the investigators collect user and patient feedback on the usability of the capillaroscopy system, to help develop the software and to develop the clinical report |
* Which microscope light source, from four different light wavelengths is better to see the blood vessels in skin with more melanin content. |
Participants will be asked to attend a single clinic visit where they will undergo a brief, non-invasive nailfold capillaroscopy examination, using the software-guided capillaroscopy system. |
Participants and rheumatology healthcare professionals will be invited to take part in one or more focus groups and interviews, to collect feedback and to contribute to the development of the image acquisition software and the clinical report. conditions: Systemic Sclerosis conditions: Raynaud Phenomenon studyType: OBS... |
<|newrecord|> nctId: NCT06291129 id: CAAE: 61347422.4.0000.5626 briefTitle: Gingival Health and Malocclusion Among Type 1 Diabetic Children and Adolescents overallStatus: ACTIVE_NOT_RECRUITING date: 2022-10-30 date: 2023-10-30 date: 2024-10-30 date: 2024-03-04 date: 2024-03-04 name: Universidade Federal Fluminense clas... |
<|newrecord|> nctId: NCT06291116 id: 2022/0345/HP briefTitle: Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease acronym: ETERNAL-PKD overallStatus: NOT_YET_RECRUITING date: 2025-01-01 date: 2029-05-01 date: 2029-05-01 date: 2024-03-04 date: 2024-03-04 name: University Hospital, Rouen cl... |
Experimental results suggested that stimulation of dopamine receptor type 5 (DR5) could restore the mechanosensitivity of endothelial cells, a hypothesis supported by our first results showing that local administration of dopamine improves endothelial function in patients with ADPKD. through restoration of endothelial ... |
Dopaminergic stimulation could also prevent abnormalities linked to polycystin deficiency at the renal level and we therefore hypothesize that rotigotine could slow the progression of ADPKD both at the renal and cardiovascular levels. |
This phase 2 study aims to ensure the good long-term tolerance of rotigotine in patients with ADPKD and to collect preliminary data on its renal impact. conditions: Kidney Diseases studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: ... |
<|newrecord|> nctId: NCT06291103 id: 2022/0342/HP briefTitle: Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R) acronym: BELA-M-R overallStatus: NOT_YET_RECRUITING date: 2025-01-01 date: 2031-03-01 d... |
The monitoring of dnDSA after KT and an indication graft biopsy in case of appearance, even in the absence of graft dysfunction, is not part of a routine clinical practice in all KT centers. This strategy could be a valuable option, in order to begin treatment of ABMR before graft dysfunction occurs, and therefore to i... |
<|newrecord|> nctId: NCT06291090 id: 22-0789 id: K08DA049905 type: NIH link: https://reporter.nih.gov/quickSearch/K08DA049905 briefTitle: A Multi-site Intervention to Expand Hospital Based OUD Treatment Provision overallStatus: RECRUITING date: 2023-01-18 date: 2024-04-30 date: 2025-05-01 date: 2024-03-04 date: 2024-03... |
<|newrecord|> nctId: NCT06291077 id: 2021/0391/HP briefTitle: Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO> acronym: BELAFENDO overallStatus: NOT_YET_RECRUITING date: 2025-01-01 date: 2028-01-01 date: 2028-01-01 date: 2024-03-04 date: 202... |
However, anticalcineurin inhibitors, the most widely used immunosuppressants, are involved in the occurrence of cardiovascular events, a major cause of premature death in these patients. They play an important role in the occurrence of endothelial dysfunction and increased arterial stiffness by decreasing the synthesis... |
Belatacept, a more recently developed immunosuppressant and co-stimulation signal inhibitor, has shown an anti-rejection effect similar to cyclosporine with a better cardiovascular tolerance profile. Preliminary studies are contradictory on the influence of Belatacept on arterial stiffness. Furthermore, to date, no stu... |
<|newrecord|> nctId: NCT06291064 id: IRB23-0678 briefTitle: Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer acronym: TARMAC overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-06 date: 2032-06 date: 2024-03-04 date: 2024-03-04 name: University of Chicago class: OTHER briefSummary... |
All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis. conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking:... |
<|newrecord|> nctId: NCT06291051 id: 2021/0382/HP briefTitle: Evaluation of the Safety of Electrical Spinal Cord Stimulation in Parkinson's Patients Presenting With Painful Camptocormia acronym: CAMPTOSTIM overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2028-01-01 date: 2028-01-01 date: 2024-03-04 date: 2024-0... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.